ReviewThe Australasian journal of dermatology2025
A Clinical Perspective on Melanoma Overdiagnosis.
Review in The Australasian journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluating the Performance of Artificial Intelligence in Accurately Detecting Skin Cancer: An Umbrella Review of Systematic Reviews and Meta-analyses.American journal of clinical dermatology · 2026Pooled it
- Spatial Proteomics as a Potential Decision-Support Layer for Early Melanoma: A Narrative Review.International journal of dermatology · 2026Review
- Incidence Rates of Melanoma and Lung Cancer Are Generally Low in the Lynch Syndromes and Vary AcrossCancers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overdiagnosis in melanoma is a nuanced and evolutionary issue. It may appear to be an epidemic from an epidemiological point of view; however, it is important to appreciate all perspectives. We consider overdiagnosis a necessary challenge-which drives clinicians to improve diagnostic accuracy and reduce overtreatment-pathologists to recalibrate histopathological thresholds and reduce overcalling-and researchers to develop markers of biological activity for melanoma. In this article, we present our clinical perspective on the current burden of melanoma overdiagnosis and its future value for progress in the field of melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.